Latest News
& Press Releases

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.

The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications.

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments.

Both companies received agency requests for more evidence of the effectiveness of their therapies.

Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.

Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.

Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.

The banker allegedly shared details of a series of multibillion-dollar buyouts by companies including AbbVie, GSK and Pfizer.

● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.

Event to Take Place December 11th at 4:30 P.M. ET

Enterololin uses a novel mechanism of action to attack the infection. New treatment has potential use in Crohn’s Disease. License is under existing Research and Collaboration Agreement with McMaster.

Oral MDL-001 Demonstrated Equivalence to Remdesivir and Sofosbuvir in Head-to-Head Animal Model Studies Performed at The Icahn School of Medicine at Mount Sinai and Scripps Research, and Superiority to Nirmatrelvir in a Literature Comparison of Equivalent Animal Models. The Potential First-in-Category, Direct-Acting, Broad-Spectrum Antiviral Targets A Novel Conserved Site on The Viral Polymerase Across Six Viral Families.